Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK.

Blood Adv. 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525.

PMID:
32045475
2.

"In Their Own Time": Parents Gently Push Their Autistic Youth Towards Independent Community Mobility and Participation.

Kersten M, Coxon K, Lee H, Wilson NJ.

J Autism Dev Disord. 2020 Feb 5. doi: 10.1007/s10803-020-04384-9. [Epub ahead of print]

PMID:
32026172
3.

Stress of Dialysis Nurses-Analyzing the Buffering Role of Influence at Work and Feedback.

Kersten M, Vincent-Höper S, Nienhaus A.

Int J Environ Res Public Health. 2020 Jan 28;17(3). pii: E802. doi: 10.3390/ijerph17030802.

4.

Correction to: "Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May;30(5):860-862. doi: 10.1093/annonc/mdy466. Epub 2019 Dec 4. No abstract available.

PMID:
31987359
5.

Rare but Serious: Ibrutinib Induced Liver Failure.

Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JMI.

Hemasphere. 2019 Oct 22;3(6):e307. doi: 10.1097/HS9.0000000000000307. eCollection 2019 Dec. No abstract available.

6.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR.

Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8. Epub 2019 Dec 19.

PMID:
31866281
7.

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ.

Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. [Epub ahead of print]

8.

Physical activity in patients with cancer: self-report versus accelerometer assessments.

Douma JAJ, de Beaufort MB, Kampshoff CS, Persoon S, Vermaire JA, Chinapaw MJ, van Mechelen W, Nollet F, Kersten MJ, Smit JH, Verdonck-de Leeuw IM, Altenburg TM, Buffart LM.

Support Care Cancer. 2019 Dec 9. doi: 10.1007/s00520-019-05203-3. [Epub ahead of print]

PMID:
31820127
9.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

10.

Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.

Kersten MJ, van Ettekoven CN, Heijink DM.

BMJ Case Rep. 2019 Nov 12;12(11). pii: e229946. doi: 10.1136/bcr-2019-229946.

PMID:
31722870
11.

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP.

Haematologica. 2019 Dec;104(12):2337-2348. doi: 10.3324/haematol.2019.227272. Epub 2019 Nov 7. Review.

12.

Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016.

Posthuma HLA, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16290. [Epub ahead of print]

PMID:
31682006
13.

Tailoring the amount of treatment information to cancer patients' and survivors' preferences: Effects on patient-reported outcomes.

Lehmann V, Labrie NHM, van Weert JCM, van Dulmen S, de Haes HJCJM, Kersten MJ, Pieterse AH, Smets EMA.

Patient Educ Couns. 2019 Sep 26. pii: S0738-3991(19)30432-X. doi: 10.1016/j.pec.2019.09.024. [Epub ahead of print]

PMID:
31585818
14.

Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.

VAN Vulpen JK, Sweegers MG, Peeters PHM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Schmidt ME, Ulrich CM, VAN Beurden M, Oldenburg HS, Sonke GS, VAN Harten WH, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, VAN Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-DE Leeuw IM, Brug J, May AM, Buffart LM.

Med Sci Sports Exerc. 2020 Feb;52(2):303-314. doi: 10.1249/MSS.0000000000002154.

PMID:
31524827
15.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.

PMID:
31498031
16.

Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses.

Bernard P, Savard J, Steindorf K, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvao DA, Chinapaw MJ, Stuiver MM, Griffith KA, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schmidt ME, Ulrich CM, Sonke GS, van Harten W, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Buffart LM.

J Psychosom Res. 2019 Sep;124:109746. doi: 10.1016/j.jpsychores.2019.109746. Epub 2019 Jun 23. Review.

PMID:
31443811
17.

Provider caring and structuring treatment information to improve cancer patients' recall: Does it help?

Lehmann V, Labrie NHM, van Weert JCM, van Dulmen S, de Haes HJCJM, Kersten MJ, Pieterse AH, Smets EMA.

Patient Educ Couns. 2020 Jan;103(1):55-62. doi: 10.1016/j.pec.2019.07.011. Epub 2019 Jul 10.

PMID:
31349965
18.

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ.

Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26.

19.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
20.

Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study.

van Dongen JM, Persoon S, Jongeneel G, Bosmans JE, Kersten MJ, Brug J, Nollet F, Chinapaw MJM, Buffart LM.

J Cancer Surviv. 2019 Aug;13(4):558-569. doi: 10.1007/s11764-019-00775-9. Epub 2019 Jul 8.

21.

Novel Object Recognition in Rats With NMDAR Dysfunction in CA1 After Stereotactic Injection of Anti-NMDAR Encephalitis Cerebrospinal Fluid.

Kersten M, Rabbe T, Blome R, Porath K, Sellmann T, Bien CG, Köhling R, Kirschstein T.

Front Neurol. 2019 Jun 5;10:586. doi: 10.3389/fneur.2019.00586. eCollection 2019.

22.

Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014-2017.

Martens L, Kuster S, de Vos W, Kersten M, Berkhout H, Hagen F.

Emerg Infect Dis. 2019 Jul;25(7):1297-1303. doi: 10.3201/eid2507.181556.

23.

Essential Office Procedures for Medicare Patients in Primary Care: Comparison With Family Medicine Residency Training.

Poulin EA, Swartz AW, O'Grady JS, Kersten MPM, Angstman KB.

Fam Med. 2019 Jul;51(7):574-577. doi: 10.22454/FamMed.2019.659478. Epub 2019 May 21.

24.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

25.

Effective Information Provision About the Side Effects of Treatment for Malignant Lymphoma: Protocol of a Randomized Controlled Trial Using Video Vignettes.

Labrie N, van Dulmen S, Kersten MJ, de Haes HJ, Pieterse AH, van Weert JC, van Spronsen DJ, Smets EM; INSTRUCT Group.

JMIR Res Protoc. 2019 May 2;8(5):e12453. doi: 10.2196/12453.

26.

Low-Molecular-Weight Organic Acid Complexation Affects Antimony(III) Adsorption by Granular Ferric Hydroxide.

Li X, Reich T, Kersten M, Jing C.

Environ Sci Technol. 2019 May 7;53(9):5221-5229. doi: 10.1021/acs.est.8b06297. Epub 2019 Apr 22.

PMID:
30969111
27.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P.

Haematologica. 2019 Nov;104(11):2265-2273. doi: 10.3324/haematol.2018.205476. Epub 2019 Apr 4.

28.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

29.

Development and evaluation of a training program for dialysis nurses - an intervention study.

Kersten M, Vincent-Höper S, Krampitz H, Nienhaus A.

J Occup Med Toxicol. 2019 Feb 11;14:3. doi: 10.1186/s12995-019-0223-3. eCollection 2019.

30.

Return to work experiences of patients treated with stem cell transplantation for a hematologic malignancy.

Persoon S, Buffart LM, Chinapaw MJM, Nollet F, Frings-Dresen MH, Koning S, Kersten MJ, Tamminga SJ.

Support Care Cancer. 2019 Aug;27(8):2987-2997. doi: 10.1007/s00520-018-4596-0. Epub 2018 Dec 27.

31.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.

PMID:
30520968
32.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

33.

Atrophy of the Vagus Nerve in Parkinson's Disease Revealed by High-Resolution Ultrasonography.

Walter U, Tsiberidou P, Kersten M, Storch A, Löhle M.

Front Neurol. 2018 Sep 27;9:805. doi: 10.3389/fneur.2018.00805. eCollection 2018.

34.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
35.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. doi: 10.1093/annonc/mdy322. No abstract available.

PMID:
30285219
36.

Developing a digital communication training tool on information-provision in oncology: uncovering learning needs and training preferences.

Stuij SM, Labrie NHM, van Dulmen S, Kersten MJ, Christoph N, Hulsman RL, Smets E; INSTRUCT project group.

BMC Med Educ. 2018 Sep 24;18(1):220. doi: 10.1186/s12909-018-1308-x.

37.

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM.

Br J Sports Med. 2019 Jul;53(13):812. doi: 10.1136/bjsports-2018-099191. Epub 2018 Sep 4.

PMID:
30181323
38.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. Ann Oncol. 2019 May 1;30(5):860-862. Ann Oncol. 2019 May;30(5):860-862.

39.

Integrating glycomics and genomics uncovers SLC10A7 as essential factor for bone mineralization by regulating post-Golgi protein transport and glycosylation.

Ashikov A, Abu Bakar N, Wen XY, Niemeijer M, Rodrigues Pinto Osorio G, Brand-Arzamendi K, Hasadsri L, Hansikova H, Raymond K, Vicogne D, Ondruskova N, Simon MEH, Pfundt R, Timal S, Beumers R, Biot C, Smeets R, Kersten M, Huijben K; CDG group, Linders PTA, van den Bogaart G, van Hijum SAFT, Rodenburg R, van den Heuvel LP, van Spronsen F, Honzik T, Foulquier F, van Scherpenzeel M, Lefeber DJ; CDG group, Mirjam W, Han B, Helen M, Helen M, Peter VH, Jiddeke VK, Diego M, Lars M, Katja BH, Jozef H, Majid A, Kevin C, Johann TWN.

Hum Mol Genet. 2018 Sep 1;27(17):3029-3045. doi: 10.1093/hmg/ddy213.

PMID:
29878199
40.

Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment.

Koens L, van de Ven PM, Hijmering NJ, Kersten MJ, Diepstra A, Chamuleau M, de Jong D.

Histopathology. 2018 Sep;73(3):473-482. doi: 10.1111/his.13647. Epub 2018 Jun 26.

PMID:
29758590
41.

Time-lapse 3D imaging by positron emission tomography of Cu mobilized in a soil column by the herbicide MCPA.

Kulenkampff J, Stoll M, Gründig M, Mansel A, Lippmann-Pipke J, Kersten M.

Sci Rep. 2018 May 4;8(1):7091. doi: 10.1038/s41598-018-25413-9.

42.

Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls.

van Sandwijk MS, Al Arashi D, van de Hare FM, van der Torren JMR, Kersten MJ, Bijlsma JA, Ten Berge IJM, Bemelman FJ.

Nephrol Dial Transplant. 2019 May 1;34(5):833-838. doi: 10.1093/ndt/gfy103.

PMID:
29726909
43.

How to improve sharing and application of knowledge in care and support for people with intellectual disabilities? A systematic review.

Kersten MCO, Taminiau EF, Schuurman MIM, Weggeman MCDP, Embregts PJCM.

J Intellect Disabil Res. 2018 Jun;62(6):496-520. doi: 10.1111/jir.12491. Epub 2018 Apr 25.

PMID:
29696724
44.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ.

Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14. Erratum in: Lancet Haematol. 2018 Jun;5(6):e240.

PMID:
29550382
45.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
46.

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium.

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. No abstract available.

47.

Development of a PCL-silica nanoparticles composite membrane for Guided Bone Regeneration.

Castro AGB, Diba M, Kersten M, Jansen JA, van den Beucken JJJP, Yang F.

Mater Sci Eng C Mater Biol Appl. 2018 Apr 1;85:154-161. doi: 10.1016/j.msec.2017.12.023. Epub 2017 Dec 21.

PMID:
29407143
48.

Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe.

Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U.

Hemasphere. 2018 Feb 2;2(1):e18. doi: 10.1097/HS9.0000000000000018. eCollection 2018 Jan-Feb. Review.

49.

Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.

Nijland ML, Koens L, Pals ST, Berge IJMT, Bemelman FJ, Kersten MJ.

Haematologica. 2018 Mar;103(3):486-496. doi: 10.3324/haematol.2017.169987. Epub 2017 Dec 21.

50.

Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.

Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M, Pals ST.

Blood. 2018 Mar 1;131(9):982-994. doi: 10.1182/blood-2017-07-797050. Epub 2017 Dec 6.

PMID:
29212806

Supplemental Content

Loading ...
Support Center